Natera, Inc.

NTRA · NasdaqGS · Stock · Healthcare
$399.05
+0.86% today
Delayed price,

What Natera does

Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.

Key facts

Sector
Healthcare
Industry
Diagnostics & Research
Market cap
$57.52B
P/E (ttm)
—
Forward P/E
-1732.3
Dividend yield
0.00%
Beta
1.50
Profit margin
-7.1%
Employees
6,135
Headquarters
Austin, TX, United States
Exchange
NasdaqGS

Performance

1 Month
+8.0%
3 Months
+47.0%
6 Months
+91.5%
1 Year
+119.6%
5 Years
+336.3%
$172.8252-week range$437.41
Biggest setback — last 12 months
-25.3%
1 Dec 2025 → 23 Mar 2026
Fell from $244.55 to $182.65 — its sharpest sustained decline this year.
Biggest run-up — last 12 months
+127.1%
13 Oct 2025 → 21 Sept 2026
Ran from $181.69 to $412.56 — its strongest sustained advance this year.

Price outlook — trend & volatility model

▲ Trend: Uptrend
Price is above its 20-, 50- and 200-day averages, each stacked above the next — a classic technical uptrend structure.
HorizonBear case (−1σ)Base caseBull case (+1σ)
1 Month$346.01 (-13.3%)$399.05$460.22 (+15.3%)
3 Months$311.70 (-21.9%)$399.05$510.87 (+28.0%)
6 Months$281.39 (-29.5%)$399.05$565.92 (+41.8%)
12 Months$243.48 (-39.0%)$399.05$654.03 (+63.9%)
Statistical, not machine-learning: a random-walk (no assumed drift) volatility model built from this ticker's own realized price history, plus a purely descriptive moving-average trend read. Illustrative only — not a price target and not financial advice. The bear and bull cases sit one standard deviation (1σ) below and above today's price, a range that covers about 68% of the outcomes the model treats as plausible, not a 68% chance of either case. Annualized volatility used: 49.4%, blended from this ticker's own 3-month and 1-year realized price history. Base case is deliberately flat — this quantifies a possible range, not a directional prediction. See the full model, including wider (≈95%) bands →

Comparable companies

Recent headlines

Learn the basics

Prices and company data are delayed reference figures from public sources (Yahoo Finance, SEC EDGAR) and may be inaccurate or out of date. This page is informational only — it is not investment advice or a recommendation to buy or sell any security. Past performance does not indicate future results.